350 rub
Journal Technologies of Living Systems №9 for 2012 г.
Article in number:
Molecular pathogenesis of osteogenic sarcoma
Keywords: osteigenic sarcoma pathogenesis
Authors:
E.N. Imyanitov
Abstract:
Modern state of molecular biologic investigations in osteogenic sarcoma is represented in this review article.
Pages: 21-26
References
  1. Vousden K.H., Lane D.P. p53 in health and disease // Nat. Rev. Mol. Cell Biol. 2007. V. 8.
    P. 275 - 283.
  2. Gorlick R., Anderson P., Andrulis I. et al.Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary // Clin. Cancer Res. 2003. V. 9. № 15. P. 5442 - 5453.
  3. Papachristou D.J., Papavassiliou A.G. Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions // Int. J. Biochem. Cell Biol. 2007. V. 39. P. 857 - 862.
  4. Tang N., Song W.X., Luo J., Haydon R.C., He T.C.Osteosarcoma development and stem cell differentiation // Clin. Orthop. Relat. Res. 2008.  V. 466. P. 2114 - 2130.
  5. Iwakuma T., Lozano G., Flores E.R.Li-Fraumeni syndrome: a p53 family affair // Cell Cycle. 2005. V. 4. P. 865 - 867.
  6. Leach F.S., Tokino T., Meltzer P. et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas // Cancer Res. 1993. V. 53. Suppl. 10. P. 2231 - 2234.
  7. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest // Cell. 1995. V. 83. P. 993 - 1000.
  8. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors // Cancer Genet. Cytogenet. 2003.  V. 145. P. 1 - 30.
  9. Giacinti C., Giordano A. RB and cell cycle progression // Oncogene. 2006. V. 25.  P. 5220 - 5227.
  10. Abramson D.H., Ellsworth R.M., Kitchin F.D., Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced - // Ophthalmology. 1984. V. 91. № 11. P. 1351 - 1355.
  11. Hanahan D., Weinberg R.A. The hallmarks of cancer // Cell. 2000. V. 100. № 1. P. 57 - 70.
  12. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma // DNA Cell Biol. 2007.  V. 26. P. 1 - 18.
  13. Clark J.C., Dass C.R., Choong P.F. A review of clinical and molecular prognostic factors in osteosarcoma // J. Cancer Res. Clin. Oncol. 2008. V. 134. № 3. P. 281 - 297.
  14. Kakar S., Mihalov M., Chachlani N.A., Ghosh L., Johnstone H. Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma // J. Surg. Oncol. 2000. V. 73. P. 125 - 126.
  15. Imyanitov E.N., Moiseyenko V.M. Molecular-based choice of cancer therapy: Realities and expectations // Clin. Chim. Acta. 2007. V. 379.
    P. 1 - 13.
  16. Akiyama T., Dass C.R., Choong P.F. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway // Mol. Cancer Ther.
    2008. V. 7. № 11. P. 3461 - 3469.
  17. Hayden J.B., Hoang B.H. Osteosarcoma: basic science and clinical implications // Orthop. Clin. North Am. 2006. V. 37. P. 1 - 7.
  18. Kerbel R.S. Tumor angiogenesis // New Engl. J. Med. 2008. V. 358. P. 2039 - 2049.
  19. Kaya M., Wada T., Akatsuka T. et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis // Clin. Cancer Res. 2000. V. 6. P. 572 - 577.
  20. Rodriguez N.I., Hoots W.K., Koshkina N.V. et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases // J. Pediatr. Hematol. Oncol. 2008. V. 30. P. 507 - 512.